Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Cancer Stem Cell Therapy Market Outlook 2020 - Competitive Landscape Report - Research and Markets


News provided by

Research and Markets

03 May, 2016, 19:03 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/Research and Markets)

DUBLIN, May 4, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Cancer Stem Cell Therapy Market Outlook 2020" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO )

Recombinant technology has improved significantly in past years due to which better therapeutics are expected to be developed in coming years. Many cancer drugs have been developed by utilization of these techniques. Cancer stem cell therapies are also expected to be developed with its help. They are expected to have superior therapeutic effects as compared to conventional therapeutics. With time, mass production is also expected to improve with improve in technology. Higher production at lower cost will allow the pharmaceutical companies to gain more market shares. They will be able to commercialize highly effective cancer stem cell therapeutics at lesser prices. In this way, they will be able to effectively compete in already overcrowded cancer therapeutics segment across the globe.

Utilization of cancer stem cells is expected to play an important role in treatment of various cancers like breast and lung cancer. Other cancers like pancreatic cancer, gastric cancer and other cancers which have been studied to lesser extent are going to have significant boost. For this, they have to identify unique features related to different cancers. Investigators are developing biochips which are expected to identify different kind of cancers. Development of this technology requires significant investments along with development of associated technology. It will allow the investigators to generate result with high confidence levels. Some time is expected to be consumed during development of these biochips.

Investigators are looking for biomolecules with therapeutic efficacy that could be used in case of cancer stem cells. Micro RNA has been identified as potential candidate which can effectively counteract the cancer stem cells. Such inhibitors are expected to have high specificity due to which lesser side effects are expected to be developed. Many properties of micro RNAs has yet to be deciphered because their side effects are not known. Concerns related to their effect on normal genes have been raised by several researchers that may hamper normal cellular activities. Most of the work has been done at laboratory levels due to which lots of time is expected to be consumed in their commercialization. Cost of these therapeutics is also a major concern as they will be out of access of several cancer patients.

Development of targeted drugs is going to play an important role in development in counteracting cancer stem cell therapy. These drugs are expected to have high specificity due to which normal cells will be spared during treatment. They will prevent the cancerous cells to develop resistance so that they won't become recalcitrant. It will also prevent the development of new cancerous cells in the body. By preventing metastasis, spread of cancer cells in different body parts would be checked. Investigators are developing drug discovery systems which would be able to find new lead molecules for developing cancer stem cell therapies. Only few candidate molecules are able to effectively eliminate cancer stem cells. As a result, significant time is consumed in the development of cancer stem cell therapies.

Key Topics Covered:

1. Introduction to Stem Cells

2. Classification of Stem Cells
2.1 Basis of Ability to Differentiate
2.2 Basis of Origin
2.3 Basis of their Source

3. Stem Cell Transplants Classification
3.1 Autologous Stem Cell Transplants
3.2 Allogeneic Stem Cell Transplants
3.3 Syngeneic Stem Cell Transplants

4. Cancer Stem Cell Therapy Mechanism of Action
4.1 Targeting Signaling Pathways
4.1.1 Hedgehog Signaling Pathway
4.1.2 Notch Signaling Pathway
4.1.3 WNT Signaling Pathway
4.2 Targeting Cell Surface Markers
4.3 Targeting miRNA Expression

5. Global Cancer Stem Cell Market Analysis
5.1 Current Market Scenario
5.2 Global Cancer Stem Cell Therapies Pipeline Overview

6. Global Cancer Stem Cell Market Dynamics
6.1 Favorable Market Parameters
6.2 Commercialization Challenges

7. Global Cancer Stem Cell Market Future Outlook

8. Global Cancer Stem Cell Clinical Pipeline by Company & Phase
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-I/II
8.6 Phase-II
8.7 Phase-III

9. Discontinued & No Development of Cancer Stem Cell in Clinical Pipeline by Company & Phase
9.1 Discontinued
9.2 No Development Reported

10. Competitive Landscape
10.1 Aldagen
10.2 Apceth
10.3 Benitec Biopharma
10.4 Celgene Corporation
10.5 Cellonis Biotechnologies
10.6 Caladrius Biosciences
10.7 Commence Bio
10.8 ExCellThera
10.9 Galena Biopharma
10.10 Gamida Cell
10.11 Genexine
10.12 ImmunoCellular Therapeutics
10.13 K-STEMCELL
10.14 Medipost
10.15 Mesoblast
10.16 Novartis
10.17 Nuo Therapeutics
10.18 OncoCyte Corporation
10.19 Pluristem Therapeutics
10.20 ReNeuron
10.21 Sangamo BioSciences
10.22 Takeda
10.23 Vericel Corporation

For more information visit http://www.researchandmarkets.com/research/kv65vn/global_cancer


Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.